Kesmalea Therapeutics is a biotech startup focusing on the discovery of novel protein degraders.
Kesmalea Therapeutics has raised $6.0M in total funding. The most recent round was Series A. The last funding was announced in January 2023.
Kesmalea Therapeutics's investors include Oxford Science Enterprises, BioInnovation Institute, Syncona Partners LLP.
Kesmalea Therapeutics is headquartered in London, United Kingdom.
Kesmalea Therapeutics is a biotech startup focusing on the discovery of novel protein degraders.
Kesmalea Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kesmalea Therapeutics — Funding & Investors." VCBacked, January 1, 2023, https://www.vcbacked.co/company/kesmalea-therapeutics. Accessed September 29, 2026.
VCBacked. (2023). Kesmalea Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/kesmalea-therapeutics
{{cite web |title=Kesmalea Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kesmalea-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated